Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT00338728
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT00338039
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Preop Chemoradiation Resectable Pancreas
- Conditions
- Interventions
- First Posted Date
- 2006-06-14
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00336648
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-06-14
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 273
- Registration Number
- NCT00336791
- Locations
- 🇪🇸
Grupo Español de Investigacion en Cancer de Mama, Madrid, Spain
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
🇲🇽Centro Medico Nacional de Occidente, Guadalajara, Mexico
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
- Conditions
- Interventions
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00330564
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT00329043
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase II 5-Azacytidine Plus VPA Plus ATRA
- Conditions
- Interventions
- First Posted Date
- 2006-05-16
- Last Posted Date
- 2012-06-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00326170
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
- Conditions
- Interventions
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT00323557
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00317772
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00317720
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States